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Abstract 
 
Background:  The risk of sudden cardiac death (SCD) in patients with heart failure following 
CABG has not been examined in a contemporary clinical trial of surgical revascularization. This 
analysis describes the incidence, timing and clinical predictors of SCD after CABG. 
Methods: Patients enrolled in the Surgical Treatment of Ischemic Heart Failure (STICH) trial 
who underwent CABG with or without surgical ventricular reconstruction (SVR) were included. 
We excluded patients with prior ICD and those randomized only to medical therapy. The 
primary outcome was SCD as adjudicated by a blinded committee. A Cox model was used to 
examine and identify predictors of SCD. The Fine and Gray method was used to estimate the 
incidence of SCD accounting for the competing risk of other deaths.  
Results: Over a median follow-up of 46 months, 113 patients of 1411 patients who received 
CABG without (n = 934) or with SVR (n = 477) had SCD; 311 died of other causes. The mean 
LVEF at enrollment was 28±9%. The 5-year cumulative incidence of SCD was 8.5%. Patients 
who had SCD and those who did not die were younger and had fewer comorbid conditions than 
those who died for reasons other than SCD. In the first 30 days after CABG, SCD (n=5) 
accounted for 7% of all deaths. The numerically greatest monthly rate of SCD was in the 31-90 
day time period. In a multivariable analysis including baseline demographics, risk factors, 
coronary anatomy and LV function, ESVI and BNP were most strongly associated with SCD. 
Conclusions: The monthly risk of SCD shortly after CABG among patients with a low LVEF is 
highest between the first and third month, suggesting that risk stratification for SCD should 
occur early in the postoperative period, particularly in patients with increased preoperative ESVI 
and/or BNP. 
Clinical Trial Registration: NCT0002359 (www.stichtrial.org) 
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Clinical Perspective  
What is new? 
 The timing of sudden cardiac death (SCD) in patients with heart failure and coronary 
disease was found to be highest during the first and third months after coronary artery 
bypass surgery (CABG). 
 In this analysis, several clinical, echocardiographic and biochemical factors were found 
to be significantly associated with the risk of SCD particularly preoperative ESVI and/or 
BNP.  
What are the clinical implications? 
 Patients with ischemic cardiomyopathy who undergo CABG may need to be risk 
stratified prior to 90 days after CABG to help prevent SCD. 
 Pre-operative clinical predictors can help inform early SCD risk stratification. 
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Introduction 
Patients with coronary artery disease and those with left ventricular dysfunction are thought to be 
at increased risk for sudden cardiac death (SCD).1 While the implantable cardioverter-
defibrillator (ICD) reduces SCD in patients with coronary artery disease and a moderately 
depressed left ventricular ejection fraction (LVEF),2-5 ICD implantation at the time of coronary 
artery bypass graft surgery (CABG) did not improve survival in a trial conducted in the 1990s.1,6 
While surgical revascularization may improve LVEF in a subset of patients,7 strategies to predict 
LVEF improvement after CABG are not validated in the context of current guideline directed 
medical therapy. Improvement in LVEF after revascularization might render ICDs unnecessary; 
however, patients who undergo CABG with or without improvement in LVEF may remain at 
risk for SCD.8 Also, there may be a delay between CABG and improvement in LVEF during 
which patients may be at risk for SCD.  
 
The risk of SCD and how that risk might change over time after CABG is uncertain. Although 
most randomized clinical trials of primary prevention ICDs required a 90-day waiting period 
after CABG before implanting an ICD, the 2008 practice guidelines on device-based rhythm 
management did not mandate any waiting period after surgical revascularization by CABG.9 
Nonetheless, many major payers including the Centers for Medicare and Medicaid Services do 
not reimburse hospitals and health care providers for primary prevention ICDs implanted within 
90 days after CABG and therefore, in the USA, ICD therapy is usually deferred. Therefore, it is 
important to determine the magnitude of SCD risk in heart failure patients recovering from 
CABG. This analysis describes the incidence, timing and clinical predictors of SCD after CABG 
in patients with coronary artery disease and a low LVEF. 
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Methods   
Study Population 
This study includes patients enrolled in the Surgical Treatment of Ischemic Heart Failure 
(STICH) trial with an LVEF ≤ 35% who underwent CABG or CABG plus surgical ventricular 
reconstruction (SVR). The STICH study design and results of the surgical revascularization and 
surgical ventricular reconstruction components have been previously described.10-13 Briefly, the 
study enrolled patients who were candidates for at least two of the three possible therapeutic 
options, medical therapy alone, medical therapy plus CABG or medical therapy plus CABG and 
SVR. Of the 2136 patients randomized, we excluded patients who were randomized to medical 
therapy only (n=602), those randomized to CABG but did not receive CABG (n=74), those with 
ICD or pacemakers for resynchronization prior to randomization (n=44) and those who received 
an ICD or pacemaker after randomization but prior to CABG (n=5) leaving 1411 patients eligible 
for this analysis.  The study complied with the Declaration of Helsinki, and the locally appointed 
ethics committee approved the research protocol.  Informed consent was obtained from the 
subjects or their legally authorized representatives.   
 
Study Outcomes 
A blinded committee adjudicated all deaths using pre-specified definitions of causes of death. 
SCD was defined by this committee as death that occurred suddenly and unexpectedly and 
judged to be due to a cardiovascular cause as previously described.14  
 
Statistical Analysis 
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Baseline or pre-operative characteristics of patients are presented as means and standard 
deviations for continuous variables, and frequencies and percentages for categorical variables. 
Data are presented for 3 groups of patients: 1) patients who had SCD, 2) patients who died of 
causes other than SCD, and 3) patients who did not die by the end of the study follow-up.  Group 
comparisons with respect to baseline clinical characteristics were performed using the Kruskal-
Wallis test for continuous variables and the conventional chi-square test for categorical variables.  
 
Cox proportional hazard models were used to examine individual relationships of candidate 
clinical characteristics and SCD, censoring other deaths at the time of death.15  Clinical 
characteristics included in the model were baseline patient demographics, medical history, prior 
cardiac procedures, presenting characteristics of heart failure (New York Heart Association 
[NYHA] heart failure class), Canadian Cardiovascular Society [CCS] angina, baseline laboratory 
measures, baseline medications, coronary anatomy, left ventricular function measures and 
volumes, six minute walk distance, and surgical details.  Candidate variables also include 
biomarkers (such as B-type natriuretic peptide [BNP] and tumor necrosis factor receptor [TNFR] 
1) and echocardiographic diastolic function variables such as E/A ratio, e velocity, deceleration 
time and right ventricular dysfunction. Of note, LVEF, end systolic volume index (ESVI) and 
other echocardiographic variables as above were independently measured in a blinded fashion by 
STICH core laboratories as previously described.16    
 
Only a few of the included variables had greater than 2% missing data. The magnitude of 
missing data for the biomarkers and diastolic function parameters was high at 15-35%; this was 
addressed by the multiple imputation method, in which 25 multiply-imputed datasets (with 
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missing values imputed) were created. Imputed datasets were used in the univariable and 
multivariable model analyses, where the results from the 25 datasets were appropriately 
combined.  Variables with a significant (P<0.05) or marginally significant relationship (P<0.10) 
with SCD in the univariable models were included in the multivariable models. Backward 
elimination was used to determine factors that were statistically significant (p<0.05) in a 
multivariable model for SCD. 
 
Given the competing risk of SCD and other modes of death, cumulative incidence rates for SCD 
and other death were estimated using the Fine and Gray method when SCD and other death rates 
were reported.17  The conditional SCD rates per month for different time intervals during follow-
up were calculated using the cumulative incidence rate of SCD.  For each time interval, the SCD 
rate per month is based on the difference between the cumulative incidence SCD rates at the end 
and the beginning of the time interval divided by the number of months for the time interval, 
under the condition that the patients survived to the beginning of the time interval.  Confidence 
intervals for the SCD rates per month were obtained using bootstrapping methods. 
SAS statistical software (version 9.2 or higher) was used in all analyses (SAS Institute, Cary 
NC).  All statistical tests were two-sided and performed at a level of significance of α=0.05.  
 
Results  
Of the 1411 patients included in this analysis, 934 patients received CABG, and 477 received 
CABG plus SVR. During the median follow-up period of 46 months, 234 patients (16.6%) 
received an ICD. There were 113 (8.0%) and 311 (22.0%) patients who died from SCD and other 
causes of death, respectively. Baseline or pre-operative characteristics comparing patients who 
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died from SCD, other causes of death and those who did not die are shown in Table 1. Patients 
who had SCD were younger, had fewer co-morbid conditions, and lower NYHA heart failure class 
than those who died from other causes.  Patients who died from SCD had higher diastolic blood 
pressure and used more digoxin. Diuretics were used more frequently in all patients who died 
compared with those who lived. Patients who died of causes other than SCD were more likely to 
have three-vessel disease compared with patients who died suddenly. While LVEF was similar in 
patients who died of SCD and those who died of other causes, ESVI was higher in patients who 
died suddenly. 
 
Cumulative incidence rates of SCD and other death over the 5-year follow-up period after CABG 
are shown in Table 2. The 1-year, 3-year and 5-year cumulative incidence of SCD after CABG in 
this patient population with low LVEF is 2.8%, 6.1% and 8.5% respectively. The conditional risk 
of SCD per month over different time intervals after revascularization is shown in Figure 1. In the 
first 30 days after CABG, the risk of SCD was 0.35% (95% CI, 0.15%-0.85%). The risk of SCD 
per month was numerically highest during the 31-90 day window [0.43% (95% CI 0.21%-0.67%)], 
although it was only slightly higher than the risk during the first month.  After 6 months, the risk 
per month decreased to 0.14% (95% CI 0.07%-0.24%) and remained relatively stable thereafter. 
 
The results of the univariable analyses on the relationship between baseline characteristics and 
SCD are shown in Table 3. Variables that have significant (p<0.05) or marginally significant 
(p<0.10) association with SCD in the univariable models are listed in Table 3 by the magnitude of 
their univariable chi-square statistics. Of all the variables studied, baseline BNP (chi-
square=16.85, p<0.001) and ESVI (chi-square=16.53, p<0.001) are the most strongly associated 
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with SCD. Other factors found to be associated with increased SCD risk included renal function, 
LVEF, right ventricular dysfunction, diuretic use, coronary artery disease index, history of atrial 
fibrillation/flutter, mitral regurgitation, stroke and intra-aortic balloon pump use. Statin use, 
hyperlipidemia, sodium level and having CABG plus SVR were found to be associated with lower 
SCD. 
 
Variables found to be independently and significantly associated with SCD in the multivariable 
model are listed in Table 4.  In the final multivariable model, ESVI was the strongest factor 
associated with SCD followed closely by BNP. Other factors associated with SCD are statin use, 
Duke Coronary Artery Disease Index, baseline sodium level, history of atrial fibrillation, and 
having received CABG plus SVR surgery. Figure 2 shows that as the ESVI increases, the 5-year 
risk of SCD increases as well (12.4% vs 5.7% for those in the 4th vs. 1st quartile of ESVI). Higher 
BNP value, high Duke Coronary Artery Disease Index, lower sodium level, and history of atrial 
fibrillation were also associated with increased risk of SCD, while statin use and having received 
CABG with SVR appeared to be associated with a lower risk of SCD. None of the factors in the 
final multivariable model were highly discriminatory between SCD and death from other causes. 
The c-index for the final selected multivariable model for SCD was 0.70.  
 
Discussion   
This paper has three main findings. First, in patients with a depressed LVEF and coronary artery 
disease undergoing CABG with or without SVR, the 5-year cumulative incidence of SCD was 
8.5%. Second, the monthly risk of SCD was greatest between the first and third months after 
CABG and decreased subsequently remaining nearly constant after 6 months. Third, we 
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identified several factors that are significantly associated with the risk of SCD including baseline 
ESVI, BNP, statin use, the Duke coronary artery disease index, serum sodium concentration, 
history of atrial fibrillation/flutter and having received CABG with SVR. Of these variables, 
baseline ESVI and BNP were most strongly associated with SCD. While baseline or pre-
operative ESVI was also associated with death from other causes, it was more strongly 
associated with SCD than LVEF and, therefore, may be useful for determining which post-
CABG patients might benefit from early interventions to reduce the risk of SCD. 
 
In the STICH trial, CABG with medical therapy compared to medical therapy alone significantly 
reduced the risk of SCD as well as pump failure death and fatal MI death with the protective 
effect of CABG being most prominent beyond two years after CABG.11,13,14 This analysis shows 
the monthly risk of SCD to be greatest between the first and third months after CABG. While 
overall SCD numbers are a low proportion of overall deaths, this observation is important as it 
challenges the current practice in the United States of postponing risk stratification for SCD and 
supports the pursuit of identifying those patients at high risk for SCD early after CABG.  
 
The best method for risk stratifying post-CABG patients for SCD is yet to be determined; 
however, data from this analysis may help inform this process. We identified several clinical, 
echocardiographic, and blood test factors that are significantly associated with SCD. Unique to 
our model is the incorporation of echocardiographic data, biomarker data and medications. 
Interestingly, beta-blocker use was not significantly associated with SCD presumably due to the 
very high rates of use in this patient population. The observation in this population that baseline 
ESVI appeared to be more strongly associated with SCD than LVEF is interesting, and probably 
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due in part to the universally depressed baseline LVEF mandated by protocol in this cohort. Our 
analysis did not incorporate follow-up postoperative LVEF data including at the time of the SCD 
event, so any conclusions regarding relationships between post-CABG LVEF and SCD would be 
largely speculative.7 Future studies should focus on the relationship between follow-up LVEF 
and risk of SCD after CABG and should explore the role of other echocardiographic parameters 
and other imaging modalities in the risk stratification of post-CABG patients for SCD.  
 
Even if accurate risk stratification of post-CABG patients for SCD is achievable, there is still 
great uncertainty as to how one would reduce this risk shortly after CABG. The CABG-PATCH 
trial showed no benefit from an ICD implanted at the time of CABG.1 It may be that ICD 
implantation at the time of CABG is only beneficial in high-risk patients. It is also possible that 
the wearable defibrillator is a beneficial strategy early on with a plan to pursue an ICD if the 
LVEF does not improve to > 35% more than 90 days after CABG.18 The advantage of the 
wearable defibrillator is it is non-invasive and does not commit patients to a lifelong therapy like 
the ICD especially if their LVEF becomes normal or near-normal. While data on the efficacy of 
the wearable defibrillator in this setting are lacking, a science advisory from the American Heart 
Association endorsed by the Heart Rhythm Society included a IIa recommendation on the use of 
wearable defibrillators after revascularization.19  
 
As a post-hoc analysis our observations must be interpreted with caution; however, this is to date 
the most comprehensive analysis of SCD in a post-CABG patient population. Patients enrolled in 
STICH may not be representative of patients seen in routine clinical practice. This analysis 
includes patients who received CABG and CABG plus SVR although the vast majority of 
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patients in clinical practice receive CABG only. We pursued this approach as the overall 
mortality in these two groups was not significantly different with the hazard ratio for all-cause 
mortality of 1.0 among those randomized to CABG or CABG plus SVR.12 While the rates of 
SCD were higher among those who received CABG than those patients who underwent CABG 
plus SVR, the increase in SCD was offset by a corresponding and equalizing increase in non-
SCD (Table 5). Whether SVR partially mitigates SCD risk relative to CABG is consistent with 
the construct posited in prior reports that exclusion of LV scar may diminish the burden of 
ventricular tachycardia as a substrate for SCD but is of unclear clinical impact in the era of ICD 
availability and the results of the STICH SVR study.12,20 By affecting ESVI21 and 
hemodynamics, SVR may have an antiarrhythmic effect; alternatively, SVR may result in scar 
tissue at the surgical incisions creating a potentially arrhythmogenic substrate. In STICH, the 
SVR patients were not followed long-term; therefore we looked at SCD in a 5-year window as 
opposed to a 10-year window. Overall arrhythmic deaths in this analysis are a small proportion 
of all deaths and although SCD was centrally adjudicated using pre-specified and well-accepted 
criteria, not all SCD events could be attributed to a ventricular arrhythmia and such granular data 
were not available. Unfortunately, we did not have data on ICD shocks or aborted SCA during 
follow-up. Finally, our model included baseline characteristics some of which might be affected 
by CABG, and our analysis does not account for changes that may have resulted from CABG. 
 
Conclusions 
Among patients with a low LVEF undergoing CABG with or without SVR, the overall risk of 
SCD was low relative to all deaths. The risk of SCD peaked during the first and third month post 
CABG and subsequently declined and remained stable after 6 months. This observation suggests 
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that patients with ischemic cardiomyopathy who undergo CABG may need to be risk stratified 
and potentially treated to prevent SCD prior to 90 days after CABG. Several pre-operative 
clinical, echocardiographic and biochemical factors are significantly associated with the risk of 
SCD that could inform SCD risk stratification. Future studies should examine the relationship 
between follow-up LV characteristics and risk of SCD after CABG, and define the best strategies 
for preventing SCD early after CABG.  
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Figure Legends 
 
 
Figure 1:  Conditional risk of sudden cardiac death per month for different time intervals after 
coronary artery bypass graft surgery 
 
Figure 2:  Cumulative incidence rates of sudden cardiac death after coronary artery bypass 
grafting by ESVI quartiles 
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Table 1. Baseline characteristics of patients who, after CABG with or without SVR, died suddenly 
compared with those who died of other causes and those who did not die 
 Characteristics: No. (%) 
All 
patients 
(N=1411) 
SCD 
(n=113) 
Other 
deaths 
(n=311) 
No death  
(n=987) p-value 
  
Age  61 ± 10 61±10 65±9 60±9 <0.001 
 
Male  1212 (86) 99 (88) 268 (86) 845 (86) 0.836 
 
White 1153 (82) 93 (82) 270 (87) 790 (80) 0.026 
 
Medical History      
 
    Stroke 94 (7) 11 (10) 35 (11) 48 (5) <0.001 
 
    Diabetes 518 (37) 44 (38) 140 (45) 335 (34) 0.002 
 
    Hypertension 839 (59) 61 (54) 197 (63) 581 (59) 0.174 
 
    Hyperlipidemia 947 (67) 65 (58) 199 (64) 683 (69) 0.017 
 
    Peripheral vascular disease  208 (15) 20 (18) 64 (21) 124 (13) 0.002 
 
    Chronic kidney disease  108 (8) 15 (13) 45 (15) 48 (5) <0.001 
 
    Atrial flutter/fibrillation  161 (11) 18 (16) 59 (19) 84 (9) <0.001 
 
    Prior CABG 36 (3) 2 (2) 16 (5) 18 (2) 0.005 
 
    NYHA heart failure class     <0.001 
 
        I 132 (9) 9 (8) 22 (7) 101 (10)  
 
        II 655 (46) 57 (50) 124 (40) 474 (48)  
 
        III 560 (40) 41 (36) 134 (43) 385 (39)  
 
       IV  64 (5) 6 (5) 31 (10) 27 (3)  
 
    Diastolic blood pressure 74 ± 11 75±10 73±12 75±11 0.052 
 
    Three vessel coronary disease 909 (64) 70 (62) 218 (70) 621 (63) 0.060 
 
    LVEF% 28 ± 9 26±9 26±8 29±9 <0.001 
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    ESVI 83 ± 32 93±37 89±35 79±31 <0.001 
     
    EDVI 116 ± 40 127±42 124±44 112±38 <0.001 
     
    BNP 442 ± 501 622±609 568±664 381±403 <0.001 
     
    Mitral regurgitation     <0.001 
         
       None or Trace 513 (37) 36 (32) 90 (29) 387 (39)  
         
       Mild (<2+) 655 (47) 51 (46) 153 (50) 451 (46)  
         
       Moderate (3+) 188 (13) 19 (17) 46 (15) 123 (13)  
   
      Severe (4+) 46 (3) 6 (5) 20 (7) 20 (2)  
 
Medications      
 
    Beta-blocker 1202 (85) 96 (85) 247 (79) 859 (87) 0.004 
 
    Digoxin 230 (16) 25 (22) 61 (20) 144 (15) 0.024 
 
    ACE-I/ARB 1249 (89) 95 (84) 277 (89) 877 (89) 0.301 
 
    Antiarrhythmic drug use 165 (12) 17 (15) 48 (15) 100 (10) 0.021 
 
    Statin 1090 (77) 78 (69) 228 (73) 784 (79)  0.008 
 
     Diuretic (loop/thiazide) 861 (61) 84 (74) 224 (72) 553 (56) <0.001 
 
     Diuretic (potassium sparing) 566 (40) 45 (40) 154 (50) 367 (37)  <0.001 
 
CABG=coronary artery bypass graft, NYHA=New York Heart Association, EF=ejection fraction, ESVI=end 
systolic volume index, EDVI=end diastolic volume index, BNP=B-type Natriuretic peptide, ACE-I= 
angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker 
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Table 2.  Cumulative Number of Events and Cumulative Incidence Rate (%) of Sudden Cardiac 
Death and Other Death for Different Time Points after Surgery among 1411 Patients 
 
 
Time after 
Surgery 
 
Sudden Cardiac Death 
 
Other Death 
Cumulative 
Number of 
Deaths 
Cumulative Incidence 
Rate (%) and 95% CI 
Cumulative 
Number of 
Deaths 
Cumulative Incidence 
Rate (%) and 95% CI 
 
30 days 
 
5 0.4 (0.2, 0.9) 65 4.6 (3.7, 5.7) 
 
90 days 
 
17 1.2 (0.7, 2.0) 90 6.4 (5.2, 7.7) 
 
6 months 
 
28 2.0 (1.4, 2.8) 114 8.1 (6.8, 9.6) 
 
1 year 
 
40 2.8 (2.1, 3.8) 148 10.5 (9.1, 12.0) 
 
3 years 
 
86 6.1 (4.9, 7.6) 231 16.4 (14.6, 18.5) 
 
5 years* 
 
107 8.5 (7.2, 10.1) 300 25.3 (22.9, 28.0) 
*There were 6 sudden cardiac deaths and 11 other deaths happened during the follow-up 
period that was “> 5 years” after the surgery.   
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Table 3. Baseline variables predicting sudden cardiac death in univariate analyses 
 
Variable Wald Chi-Square HR 95% CI p-value 
 
BNP in 100pg/ml increment* 
 
16.85 1.21 1.10-1.33 <0.001 
 
ESVI in 20 ml/m2 increment 16.53 1.22 1.11-1.35 <0.001 
 
Creatinine (mg/dL) 13.02 1.58 1.23-2.03 <0.001 
 
LVEF in 5% increment 10.75 0.83 0.74-0.93 0.001 
 
Duke CAD index in 10 point increments 10.62 1.15 1.06-1.26 0.001 
 
Chronic renal insufficiency 9.63 2.37 1.37-4.08 0.002 
TNF receptor* 
        1000-1800 in 200pg/mL increments 
        >1800 in 200pg/mL increments 
9.54  
1.16 
1.02 
 
1.00-1.34 
1.00-1.04 
0.009 
 
Diuretics (loop/thiazide or potassium sparing) 8.34 2.01 1.25-3.23 0.004 
 
Statin 6.66 0.59 0.40-0.88 0.010 
 
RV dysfunction* 6.22 1.33 1.06-1.65 0.013 
 
New onset ventricular arrhythmia 6.15 5.97 1.45-24.53 0.013 
 
Hyperlipidemia 5.91 0.63 0.43-0.91 0.015 
 
Atrial flutter/fibrillation 5.60 1.84 1.11-3.04 0.018 
 
Mitral regurgitation* 5.31 1.31 1.04-1.64 0.021 
E/A ratio overall* 
     1.6-2.0 in 0.1 increments 
     >2.0 in 0.1 increments 
5.20  
1.19 
0.96 
 
1.03-1.39 
0.90-1.02 
0.074 
 
Sodium in mEq/L 4.40 0.95 0.91-1.00 0.036 
 
E velocity in m/s* 4.29 2.29 1.04-5.04 0.039 
 
Deceleration time in 10ms increments* 4.06 0.91 0.84-1.00 0.044 
 
Stroke 3.53 1.82 0.97-3.38 0.060 
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Received mitral valve procedure 3.46 1.54 0.98-2.44 0.063 
 
Received CABG + SVR 3.43 0.66 0.42-1.02 0.064 
 
IABP for low cardiac output 3.03 1.97 0.92-4.24 0.082 
 
BNP=B-type natriuretic peptide, ESVI=end systolic volume index, LVEF=left ventricular ejection 
fraction, CAD=coronary artery disease, TNF=tumor necrosis factor, RV=right ventricle, 
CABG=coronary artery bypass graft, SVR=surgical ventricular reconstruction, IABP=intra-aortic 
balloon pump 
HR=hazard ratio, CI=confidence interval 
 
Variables with 10 or more patients with missing data are marked by “* “.   The number and 
percent of patients with missing data are as follows:  BNP: 493 (34.9 %); TNFR1: 493 (34.9%); 
Deceleration time: 434 (30.8%); E/A ratio: 402 (28.5 %);  E velocity: 337 (23.9% );  RV 
dysfunction: 209 (14.8%).   
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Table 4. Baseline variables predictive of sudden cardiac death in a multivariable model 
 
 Variable Wald Chi-Square HR 95% CI p-value 
 
ESVI in 20 ml/m2 increment 9.59 1.18 1.06-1.31 0.002 
 
BNP in 100 pg/mL increment up to 750 9.51 1.16 1.06-1.28 0.002 
 
Statin use 7.52 0.57 0.38-0.85 0.006 
 
Duke CAD index in 10 point increments 5.71 1.11 1.02-1.22 0.017 
 
Sodium in mEq/L 5.21 0.95 0.90-0.99 0.023 
 
History of atrial fibrillation/flutter 5.01 1.79 1.08-2.98 0.025 
 
Received CABG+ SVR 4.02 0.64 0.41-0.99 0.045 
 
ESVI=end systolic volume index, BNP=B-type natriuretic peptide, CAD=coronary artery disease, 
CABG=coronary artery bypass graft, SVR=surgical ventricular reconstruction  
HR=hazard ratio, CI=confidence interval 
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Table 5.  Cumulative Incidence Rate (%) of Sudden Cardiac Death and Other Death for Different 
Time Points after Surgery by Treatment Received 
  
Cumulative Incidence Rate (%) and 95% CI 
 
 
 
 
Time after 
Surgery 
 
SCD  
 
 
Other Death 
 
 
CABG 
(N=934) 
CABG+SVR 
(N=477) 
CABG 
(N=934) 
CABG+SVR 
(N=477) 
 
30 days 0.4 (0.2, 1.0) 0.3 (0.1, 0.6) 4.4 (3.5, 5.6) 5.0 (3.9, 6.4) 
 
90 days 1.4 (0.8, 2.2) 0.9 (0.5, 1.6) 6.1 (5.0, 7.4) 
 
6.9 (5.3, 9.0) 
 
6 months 2.3 (1.6, 3.3) 1.4 (0.9, 2.4) 7.7 (6.4, 9.4) 8.7 (6.7, 11.3) 
 
1 year 3.2 (2.4, 4.4) 2.0 (1.3, 3.1) 
 
10.1 (8.6, 11.8) 11.3 (9.2, 14.0) 
 
3 years 7.0 (5.5, 8.8) 4.4 (3.0, 6.6) 15.8 (13.9, 17.9) 17.7 (14.8, 21.1) 
 
5 years 9.6 (7.8, 11.8) 6.1 (4.1, 9.1) 24.4 (21.6, 27.6) 27.2 (23.1, 32.0) 
 
SCD=sudden cardiac death, CABG=coronary artery bypass graft, SVR=surgical ventricular 
reconstruction, CI=confidence interval 
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Figure 1 
 
 
 
SCD=sudden cardiac death; CABG=coronary artery bypass graft; There were 6 sudden cardiac 
deaths which occurred during the follow-up period that was “> 5 years” after the surgery. 
Therefore, they were not included in this figure. 
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Figure 2 
 
SCD=sudden cardiac death, CABG=coronary artery bypass graft, ESVI=end systolic volume index 
 
 
